Lundbeck

LundbeckH. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in brain diseases. For more than 50 years, we have been at the forefront of research within neuroscience. Our key areas of focus are alcohol dependence, Alzheimer's disease, bipolar disorder, depression/anxiety, epilepsy, Huntington's disease, Parkinson's disease, schizophrenia and symptomatic neurogenic orthostatic hypotension (NOH).

An estimated 700 million people worldwide are living with brain disease and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain disease - we call this Progress in Mind.

Our approximately 6,000 employees in 57 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several late-stage development programs and our products are available in more than 100 countries. We have research centers in China, Denmark and the United States and production facilities in China, Denmark, France and Italy. Lundbeck generated revenue of approximately DKK 13.5 billion in 2014 (EUR 1.8 billion; USD 2.4 billion).

Lundbeck's shares are listed on the stock exchange in Copenhagen under the symbol "LUN". Lundbeck has a sponsored Level 1 ADR program listed in the US (OTC) under the symbol "HLUYY".

www.lundbeck.com

Lundbeck RSS Channel

Display # 
Title Published Date
Kåre Schultz appointed new president and CEO of Lundbeck 06 May 2015
Lundbeck and Otsuka to co-develop Lu AF20513, an investigational vaccine against Alzheimer's disease 15 December 2013
The solid momentum continues - New Products up by 41% 06 November 2013
Takeda and Lundbeck announce FDA approval of Brintellix™ (vortioxetine) 01 October 2013
Vortioxetine, a new multimodal agent in development for the treatment of major depression 23 May 2013
Lundbeck is well on track to deliver on guidance for 2013 01 May 2013
Lundbeck announces positive results for Brintellix™ (vortioxetine) 08 April 2013
Lundbeck and Otsuka further expand their alliance and enter into collaboration 26 March 2013
Lundbeck on track to meet financial expectations and renew its product portfolio 08 August 2012
Lundbeck's Lu AE58054 meets primary endpoint 29 May 2012
Statistically significant clinical phase III results of Lu AA21004 14 May 2012
Lundbeck and Otsuka Pharmaceutical sign historic agreement 13 November 2011
Lundbeck's third quarter report 2011 - The positive momentum continues 10 November 2011
Lundbeck's first half report 2011 11 August 2011
Lundbeck's partner Mochida receives approval of Lexapro in Japan 23 April 2011
A new pharmaceutical candidate enters Lundbeck's development pipeline 30 March 2011
Lundbeck delivers at the top-end of guidance and momentum is expected to continue in 2011 24 February 2011
The clinical phase III programme commenced on zicronapine 20 January 2011
First two clinical phase III studies confirm the profile of nalmefene 03 January 2011
Lundbeck enters into drug discovery collaboration with Zenobia and Vernalis 16 December 2010

Most Popular Now

New antibiotic Zavicefta approved i…

AstraZeneca today announced that the European Commission (EC) has granted marketing authorisation for Zavicefta (ceftazidime-avibactam, previously known as CAZ AVI), a ne...

Read more

Novo Nordisk and Aarhus University …

Novo Nordisk and Aarhus University's Science and Technology faculty today signed a collaboration agreement to strengthen protein technology research and development. Unde...

Read more

AstraZeneca enters licensing agreem…

AstraZeneca today announced that it has entered into agreements that support its strategic focus on three main therapy areas; Respiratory, Inflammation and Autoimmunity, ...

Read more

Novartis adds bispecific antibodies…

Today Novartis announced that it has entered into a collaboration and licensing agreement with Xencor for the development of bispecific antibodies for treating cancer. Th...

Read more

Bristol-Myers Squibb and PsiOxus Th…

Bristol-Myers Squibb Company (NYSE: BMY) and PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an exclusive clinical collaboration agreement to evaluate the safety, to...

Read more

Bristol-Myers Squibb acquires Cormo…

Bristol-Myers Squibb Company (NYSE:BMY) and Cormorant Pharmaceuticals announced today that Bristol-Myers Squibb has acquired all of the outstanding capital stock of Cormo...

Read more

Sanofi Pasteur signs research agree…

Sanofi and its vaccines global business unit Sanofi Pasteur announced today a Cooperative Research and Development Agreement with the Walter Reed Army Institute of Resear...

Read more

Laboratory drug trials could lead t…

A new drug with the potential to reverse or slow the development of asthma is being tested by researchers at The University of Queensland. Developed by international phar...

Read more

FDA advances Precision Medicine Ini…

In support of the President’s Precision Medicine Initiative, the U.S. Food and Drug Administration has issued two draft guidances that, when finalized, will provide a fle...

Read more

Merck and Pfizer initiate Phase III…

Merck KGaA, Darmstadt, Germany, and Pfizer (NYSE: PFE) have announced the initiation of a Phase III study, JAVELIN Ovarian 100, to evaluate the efficacy and safety of ave...

Read more

Merck commits €1.5 million to the G…

Merck, a leading science and technology company, today announced it would continue to support the advancement of medical science in the field of fertility through the Gra...

Read more

Twisting and turning to target anti…

Researchers are getting closer to understanding how some natural antibiotics work so they can develop drugs that mimic them. A recent review commissioned by the British g...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest World Pharma Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]

© World Pharma News 2006 - 2016